CINGW

Cingulate Inc. Warrants

CINGW, USA

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

https://www.cingulate.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
CINGW
stock
CINGW

Fundamentals Check: What dividend growth rate does ZAPPW offer - Weekly Trend Report & Expert Curated Trade Setup Alerts baoquankhu1.vn

Read more →
CINGW
stock
CINGW

Gains Recap: Will CINGW benefit from sector rotation - Quarterly Risk Review & Safe Entry Point Alerts baoquankhu1.vn

Read more →

Showing 2 of 9

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.09

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-211.33 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-69.79 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

2.03

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Cingulate Inc. Warrants

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

No earnings data available.

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.8)
GARP
Not Attractive for GARP(0.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(1)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.